CERo Therapeutics Holdings, Inc. (CERO) annual income statement — 5-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - |
| Cost of Goods Sold | 1.09M | 1.09M | 1.16M | 1.12M | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -1.09M | -1.09M | -1.16M | -1.12M | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | 6.65% | -4.13% | - | - | - |
| Operating Expenses | 17.53M | 17.38M | 15.3M | 2.93M | 2.91M | 431.5K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 8.39M | 8.08M | 8.98M | 2.89M | 2.84M | 2.48M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 9.81M | 10.38M | 6.32M | 0 | 9.85M | 9.14M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | -668.79K | -1.09M | 351 | 40.05K | -9.78M | -11.18M |
| Operating Income | -18.36M | -18.46M | -15.3M | -2.93M | -2.91M | -332.03K |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -20.67% | -421.68% | -0.95% | -775.05% | - |
| EBITDA | -17.54M | -17.38M | -14.14M | -2.93M | 1 | 403.44K |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -16.7% | -22.91% | -382.51% | -99999900% | -100% | - |
| D&A (Non-Cash Add-back) | 816.56K | 1.09M | 1.16M | 2.93K | 2.91M | 735.47K |
| EBIT | -19.07M | -18.46M | -7.73M | -2.44M | -2.91M | -332.42K |
| Net Interest Income | -152.37K | 11.61K | 26.65K | 138.34K | 2.84M | 986.71K |
| Interest Income | 13.91K | 11.61K | 26.65K | 138.34K | 2.84M | 986.71K |
| Interest Expense | 166.29K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.34M | -1.46M | 7.57M | 491.57K | 2.84M | -385 |
| Pretax Income | -20.7M | -19.92M | -7.73M | -2.44M | -68.58K | -332.42K |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 94.82K | 599.16K | -16.87K |
| Effective Tax Rate % | 0% | 0% | 0% | -3.88% | -873.7% | 5.07% |
| Net Income | -20.7M | -19.92M | -7.73M | -2.54K | -667.74K | -315.55K |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -96.43% | -157.63% | -304789.59% | 99.62% | -111.61% | - |
| Net Income (Continuing) | -20.7M | -19.92M | -7.73M | -2.54M | -667.74K | -315.55K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.72 | -22.58 | -6.87 | -2497.20 | -19.73 | -2.75 |
| EPS Growth % | -47% | -228.68% | 99.72% | -12556.87% | -617.45% | - |
| EPS (Basic) | - | -22.58 | -6.87 | -2497.20 | -19.73 | -2.75 |
| Diluted Shares Outstanding | 28.76M | 4.23M | 120.79K | 7.35K | 7.35K | 7.35K |
| Basic Shares Outstanding | 28.76M | 4.23M | 120.79K | 7.35K | 7.35K | 7.35K |
| Dividend Payout Ratio | - | - | - | - | - | - |
Quick answers to the most common questions about buying CERO stock.
For fiscal year 2025, CERo Therapeutics Holdings, Inc. (CERO) reported total revenue of $0.0M.
CERo Therapeutics Holdings, Inc. (CERO) reported a net loss of $19.9M for the fiscal year ending 2025.